Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ig NextGen 16% SC in Primary Immunodeficiency
NCT00391131Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Apr 2007
- Primary completion
- Oct 2009
- Modality
- Biologic
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of Evogam in primary immunodeficiency (PI), sponsored by CSL Limited. Primary endpoints: Rate of serious bacterial infections and Serum IgG trough levels. Started Apr 2007; status: completed.
02
Drugs
Evogam
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT00391131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391131.